ARCHIMED completes acquisition of dental implant maker ZimVie

PALM BEACH GARDENS, Fla. - Investment firm ARCHIMED has completed its previously announced acquisition of dental implant maker ZimVie Inc. for $19.00 per share in cash, according to a press release issued Monday. The deal values ZimVie at approximately $536 million, with the final share price aligning closely with InvestingPro’s Fair Value estimate.

The transaction, which was first announced on July 20, 2025, has resulted in ZimVie’s common stock being delisted from the NASDAQ stock exchange. Prior to the acquisition, the stock had demonstrated remarkable performance, delivering a 102% return over the previous six months. For deeper insights into similar healthcare companies and their valuations, investors can access comprehensive analysis through InvestingPro’s extensive database of Pro Research Reports covering over 1,400 US equities.

ZimVie, headquartered in Palm Beach Gardens, Florida, is a global provider of dental implants, biomaterials, and digital workflow solutions for tooth replacement and restoration procedures. The company generates annual revenue of $443 million with an impressive gross profit margin of 65.3%. According to InvestingPro data, ZimVie maintains strong liquidity with a current ratio of 2.37, indicating solid financial health.

"We are excited to partner with ZimVie to accelerate its growth as a global leader in the dental implant market," said André-Michel Ballester, Managing Partner at ARCHIMED, which focuses exclusively on healthcare industries.

ARCHIMED manages €8 billion across various funds and maintains offices in Europe, North America, and Asia. The firm serves as both a strategic and financial partner to healthcare businesses in several sectors including MedTech, Biopharma Products, and Healthcare IT.

For the transaction, Centerview Partners acted as exclusive financial advisor to ZimVie, while Cravath, Swaine & Moore LLP served as legal advisor. UBS Investment Bank was the exclusive financial advisor to ARCHIMED, with Latham & Watkins LLP providing legal counsel.

The acquisition comes as part of ARCHIMED’s strategy to invest in healthcare companies. The firm claims to have been a committed impact investor since its inception.

In other recent news, ZimVie Inc. announced that its stockholders have approved the company’s acquisition by an affiliate of the healthcare investment firm ARCHIMED. The deal, valued at approximately $730 million, will offer ZimVie stockholders $19.00 in cash per share, a significant premium to the company’s recent average stock price. This acquisition is expected to close by the end of 2025, pending regulatory approvals and other conditions. Following the acquisition announcement, B.Riley downgraded ZimVie’s stock rating from Buy to Neutral, although it raised the price target to $19.00. Conversely, Barclays upgraded the stock from Underweight to Equalweight, more than doubling its price target from $9.00 to $19.00.

ZimVie also reported its second-quarter 2025 financial results, with revenue reaching $116.7 million, surpassing both B.Riley’s and consensus estimates. The company’s adjusted EBITDA was $17.5 million, exceeding expectations. In a strategic move to expand its market presence, ZimVie has entered into a distribution agreement with Osstem Implant Co., Ltd. to enhance its reach in the Chinese dental implant market. These developments highlight a period of significant activity and transformation for ZimVie Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.